Perjeta (pertuzumab) / Roche 
Welcome,         Profile    Billing    Logout  
 80 Diseases   208 Trials   208 Trials   5617 News 


«12...4243444546474849505152...7172»
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Perjeta (pertuzumab) / Roche, Tecentriq (atezolizumab) / Roche
    [VIRTUAL] Checkpoint inhibition in patients with TNBC: How robust is the data today? (Singapore) -  Sep 3, 2020 - Abstract #DGHO2020DGHO_516;    
    The addition of immune checkpoint inhibitors to cytotoxic chemotherapy has also been evaluated in phase III trials with atezolizumab and pembrolizumab for patients with advanced TNBC...Patients with advanced TNBC and expression of PD-L1 in tumor-infiltrating immune cells or in both immune and cancer cells (in particular with “combined positive score” > 10%) experience a prolonged progression-free survival with atezolizumab (IMpassion 130) or pertuzumab (KEYNOTE-355)...The promise of a longer survival and a better quality of life remains to be fulfilled. The presentation and conclusions will be updated with trial results as they appear in print or at major scientific meetings.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Preclinical, Journal:  Acquired resistance to HER2-targeted therapies creates vulnerability to ATP synthase inhibition. (Pubmed Central) -  Aug 18, 2020   
    Furthermore, combining ATP synthase inhibitor oligomycin A with trastuzumab led to regression of trastuzumab-resistant tumors in vivo. In conclusion, we identify a novel vulnerability of cells with acquired resistance to HER2-targeted antibody therapies and reveal a new therapeutic strategy to overcome resistance.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Journal:  Semi-rational Design of Target-binding Small Proteins for Cancer Treatment (Pubmed Central) -  Aug 18, 2020   
    Finally, four out of the 65 showed specific binding to HER2 with a dissociation constant (K) of 24-65 nM, and these were used for the detection of HER2-expressing cancer cells. Our design strategy will promote the development of antibody mimetics for the effective treatment of cancers and other diseases.
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche, Verzenio (abemaciclib) / Eli Lilly
    Trial initiation date, Metastases:  ACCRU-BR-1801: T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer (clinicaltrials.gov) -  Aug 16, 2020   
    P2,  N=126, Not yet recruiting, 
    Clinicians and patients can be reassured that real‐world outcomes that match or exceed those reported in pivotal clinical trials are achievable. Initiation date: May 2021 --> Sep 2020
  • ||||||||||  HS627 (pertuzumab biosimilar) / Zhejiang Hisun, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    New P3 trial, Combination therapy, Metastases:  Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel (clinicaltrials.gov) -  Aug 16, 2020   
    P3,  N=408, Recruiting, 
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Journal:  Toxicology of Trastuzumab: An Insight into Mechanisms of Cardiotoxicity. (Pubmed Central) -  Aug 14, 2020   
    This article discusses various mechanisms that have been proposed for the cardiotoxic effects of trastuzumab and the potential risk factors that can lead to cardiotoxicity. The recently approved anti-HER2 monoclonal antibodies including pertuzumab and ado-trastuzumab (T-DM1) are also discussed.
  • ||||||||||  Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) / Roche, Perjeta (pertuzumab) / Roche
    P1 data, Journal:  Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study. (Pubmed Central) -  Aug 14, 2020   
    P1
    A loading dose of 1200 mg for SC pertuzumab was selected based on approximate dose proportionality. The PK and safety results support further development of a fixed-dose coformulation combination of pertuzumab and trastuzumab for SC administration, which will be investigated in an upcoming phase III trial in patients with HER2-positive early breast cancer.
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche
    [VIRTUAL] The survival outcomes for the subsequent therapy after treatment with trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer patients (e-poster) -  Aug 14, 2020 - Abstract #EBCCI2020EBCC-I_657;    
    Thirteen (43.3%) patients were administered a regimen containing Tmab and/or lapatinib for the first subsequent line after T-DM1...Univariate analysis showed that brain metastases(P<0.004), prior use of Pmab(P=0.03) and the PFS of T-DM1(P=0.03) were significant predictive factors for the PFS of the first subsequent therapy in HER2 positive MBC patients. Conclusions This is the first report to evaluate the survival outcomes for the post-T-DM1 therapy in Japanese HER2-positive MBC patients.Our study showed brain metastases, prior use of Pmab, and PFS of T-DM1 treatment were significantly associated with the PFS of the subsequent treatment after T-DM1 for patients with HER2-positive MBC.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    [VIRTUAL] Axillary management in patients with breast cancer and positive axilla at diagnosis (e-poster) -  Aug 14, 2020 - Abstract #EBCCI2020EBCC-I_598;    
    With a 40% of complete axillary response rate to chemotherapy, sentinel node biopsy provides valid and reliable information about cancer stadification and could prevent lymphadenectomy, replacing it with radiotherapy and thus decreasing morbidity. the pathological response to systemic treatment has emerged as the most important predictive factor of disease-free survival on breast cancer.
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche
    [VIRTUAL] The survival outcomes for the subsequent therapy after treatment with trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer patients (e-poster) -  Aug 14, 2020 - Abstract #EBCCI2020EBCC-I_337;    
    Thirteen (43.3%) patients were administered a regimen containing Tmab and/or lapatinib for the first subsequent line after T-DM1...Univariate analysis showed that brain metastases(P<0.004), prior use of Pmab(P=0.03) and the PFS of T-DM1(P=0.03) were significant predictive factors for the PFS of the first subsequent therapy in HER2 positive MBC patients. Conclusions This is the first report to evaluate the survival outcomes for the post-T-DM1 therapy in Japanese HER2-positive MBC patients.Our study showed brain metastases, prior use of Pmab, and PFS of T-DM1 treatment were significantly associated with the PFS of the subsequent treatment after T-DM1 for patients with HER2-positive MBC.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    [VIRTUAL] Axillary management in patients with breast cancer and positive axilla at diagnosis (e-poster) -  Aug 14, 2020 - Abstract #EBCCI2020EBCC-I_270;    
    With a 40% of complete axillary response rate to chemotherapy, sentinel node biopsy provides valid and reliable information about cancer stadification and could prevent lymphadenectomy, replacing it with radiotherapy and thus decreasing morbidity. the pathological response to systemic treatment has emerged as the most important predictive factor of disease-free survival on breast cancer.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Trial completion, Trial completion date, Trial primary completion date:  PETRARCA: FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer (clinicaltrials.gov) -  Aug 11, 2020   
    P2/3,  N=81, Completed, 
    Herein, we report successful treatment of Stage Ⅳ breast cancer with conversion therapy. Active, not recruiting --> Completed | Trial completion date: Mar 2021 --> Jul 2020 | Trial primary completion date: Mar 2021 --> Jul 2020
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Trial completion date, Combination therapy, Metastases:  PERNETTA: Trastuzumab & Pertuzumab Followed by T-DM1 in MBC (clinicaltrials.gov) -  Aug 9, 2020   
    P2,  N=208, Active, not recruiting, 
    Active, not recruiting --> Completed Trial completion date: Jun 2020 --> Dec 2020
  • ||||||||||  Margenza (margetuximab) / MacroGenics, ZAI Lab, Perjeta (pertuzumab) / Roche
    Enrollment open:  MARGetuximab Or Trastuzumab (MARGOT) (clinicaltrials.gov) -  Aug 7, 2020   
    P2,  N=171, Recruiting, 
    PAM50 intrinsic subtyping further refines our ability to identify a subset of patients for whom chemotherapy might be spared. Not yet recruiting --> Recruiting
  • ||||||||||  Review, Journal:  Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review. (Pubmed Central) -  Aug 2, 2020   
    Parallel to this, development of ADCs in breast cancer has suffered other setbacks, including the recent failure of other agents (MM-302) as well as the suspension of a few programs (XMT-1522, ADCT-502) with the overall effect of dampening the impetus of this concept and halting/delaying the progress of drugs associated with it, particularly when immunotherapy is at the center of so many efforts...Finally, breakthroughs are occurring in the orphan triple-negative breast cancer subtype with agents targeting surface proteins. The recent results of Sacituzumab govitecan suggest substantial activity in heavily pre-treated patients and underscore the enduring relevance of antibody drug conjugates as a path towards better outcomes.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Review, Journal:  The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer. (Pubmed Central) -  Aug 1, 2020   
    The discovery of newer HER2-targeted therapies, such as Pertuzumab (Perjeta), has further added to the armamentarium of treating HER2-positive breast cancers. This review highlights recent advancements in the treatment of HER2-positive diseases, including the newer HER2-targeted therapies and immunotherapies in clinical trials, which have paved (and will further update) the way for clinical practice, and become part of the standard of care in the neoadjuvant, adjuvant or metastatic setting.
  • ||||||||||  Review, Journal:  HER2-positive advanced breast cancer treatment in 2020. (Pubmed Central) -  Jul 30, 2020   
    Other agents - including other antibody drug conjugates and bispecific antibodies as well as combinations - will lead to further changes in coming years. Additionally, should the numerous putative biomarkers thus identified ever come into use at the clinic, choice of treatment and response evaluation may be substantially changed.
  • ||||||||||  paclitaxel / Generic mfg., trastuzumab biosimilar / Hetero
    Journal:  Appropriate use of trastuzumab in Lazio Region: therapeutic scenarios and estimation of possible savings for the Regional Health Service. (Pubmed Central) -  Jul 29, 2020   
    Additionally, should the numerous putative biomarkers thus identified ever come into use at the clinic, choice of treatment and response evaluation may be substantially changed. Through the use data of the different formulations available for trastuzumab and taking into account the prescriptive appropriateness (and patient preferences), it has been possible to identify a SSR scenario of economic convenience due to the greater use of the biosimilar.